| Segment Reporting Disclosure [Text Block] |
Note 21. Reportable Segments
The Company has two reportable segments: (i) e-Commerce Operations, which involves acquiring and leasing, primarily an e-commerce platform to collaborate with businesses to optimize their ability to sell their goods online, domestically, and internationally, and enabling customers and partners to optimize their e-commerce presence and revenue, and other related businesses and (ii) Healthcare Operations, which provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, compounded medications, telepharmacy services, anti-retroviral medications, medication therapy management, the supply of prescription medications to long-term care facilities, medication adherence packaging, contracted pharmacy services for 340B covered entities under the 340B Drug Discount Pricing Program, and health practice risk management.
The Company evaluates the performance of each of the segments based on profit or loss after general and administrative expenses. While the Company believes there are synergies between the two business segments, the segments are managed separately because each requires different business strategies.
The following tables present a summary of the reportable segments:
| Three Months Ended September 30, 2023 |
|
|
e-Commerce Operations |
|
|
|
Healthcare Operations |
|
|
|
Eliminations |
|
|
|
Total |
|
| Pharmacy prescription and other revenue, net of PBM fees |
|
$ |
- |
|
|
$ |
9,887,890 |
|
|
$ |
- |
|
|
$ |
9,887,890 |
|
| e-Commerce revenue |
|
|
2,930,721 |
|
|
|
- |
|
|
|
- |
|
|
|
2,930,721 |
|
| Pharmacy 340B contract revenue |
|
|
- |
|
|
|
2,471,560 |
|
|
|
- |
|
|
|
2,471,560 |
|
| Revenues, net |
|
$ |
2,930,721 |
|
|
$ |
12,359,450 |
|
|
$ |
- |
|
|
$ |
15,290,171 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
|
|
2,126,602 |
|
|
|
8,578,887 |
|
|
|
- |
|
|
|
10,705,489 |
|
| Selling, general and administrative |
|
|
1,978,743 |
|
|
|
2,268,708 |
|
|
|
(60,022 |
) |
|
|
4,187,429 |
|
| Salaries, wages and payroll taxes |
|
|
563,915 |
|
|
|
1,919,517 |
|
|
|
- |
|
|
|
2,483,432 |
|
| Professional fees |
|
|
277,872 |
|
|
|
242,854 |
|
|
|
- |
|
|
|
520,726 |
|
| Depreciation and amortization |
|
|
163,512 |
|
|
|
707,554 |
|
|
|
- |
|
|
|
871,066 |
|
| |
|
|
5,110,644 |
|
|
|
13,717,520 |
|
|
|
(60,022 |
) |
|
|
18,768,142 |
|
| Loss before other (income) expense |
|
$ |
(2,179,923 |
) |
|
$ |
(1,358,070 |
) |
|
$ |
60,022 |
|
|
$ |
(3,477,971 |
) |
| For the Nine Months Ended September 30, 2023 |
|
|
e-Commerce Operations |
|
|
|
Healthcare Operations |
|
|
|
Eliminations |
|
|
|
Total |
|
| Pharmacy prescription and other revenue, net of PBM fees |
|
$ |
- |
|
|
$ |
9,887,890 |
|
|
$ |
- |
|
|
$ |
9,887,890 |
|
| e-Commerce revenue |
|
|
8,764,237 |
|
|
|
- |
|
|
|
- |
|
|
|
8,764,237 |
|
| Pharmacy 340B contract revenue |
|
|
- |
|
|
|
2,471,560 |
|
|
|
- |
|
|
|
2,471,560 |
|
| Revenues, net |
|
$ |
8,764,237 |
|
|
$ |
12,359,450 |
|
|
$ |
- |
|
|
$ |
21,123,687 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cost of revenue |
|
|
6,495,432 |
|
|
|
8,578,887 |
|
|
|
- |
|
|
|
15,074,319 |
|
| Selling, general and administrative |
|
|
5,286,915 |
|
|
|
2,268,708 |
|
|
|
(60,022 |
) |
|
|
7,495,601 |
|
| Salaries, wages and payroll taxes |
|
|
2,119,790 |
|
|
|
1,919,517 |
|
|
|
- |
|
|
|
4,039,307 |
|
| Professional fees |
|
|
1,142,620 |
|
|
|
242,854 |
|
|
|
- |
|
|
|
1,385,474 |
|
| Depreciation and amortization |
|
|
493,271 |
|
|
|
707,554 |
|
|
|
- |
|
|
|
1,200,825 |
|
| |
|
|
15,538,028 |
|
|
|
13,717,520 |
|
|
|
(60,022 |
) |
|
|
29,195,526 |
|
| Loss before other (income) expense |
|
$ |
(6,773,791 |
) |
|
$ |
(1,358,070 |
) |
|
$ |
60,022 |
|
|
$ |
(8,071,839 |
) |
| |
|
e-Commerce Operations |
|
|
Healthcare Operations |
|
|
Eliminations |
|
|
Total |
|
| Total assets as of September 30, 2023 |
|
$ |
36,395,131 |
|
|
$ |
41,264,995 |
|
|
$ |
(11,464,939 |
) |
|
$ |
66,195,187 |
|
|